Jeppe Krog Rasmussen, Louise Conradsen og Morten Martinsen bød velkommen sammen med resten af DanCann Pharma-teamet til deres facilitet i Jylland. Formålet med besøget var at udveksle viden om eksport og investeringer inden for Europa vedrørende medicinsk cannabis samt at fremvise deres produktionsfacilitet Biotech Pharm1 ("BP1").

[image]

DanCann Pharma blev etableret i 2018 og har siden da taget store skridt i retning af at etablere sig som producent og forhandler af medicinsk cannabis. Tilbage i november blev DanCann Pharma EU-GMP-certificeret til produktion af medicinsk cannabis, og de har allerede indgået eksportaftaler for de første produktioner i 2023 og 2024. Efterspørgslen efter deres kvalitetssikrede produkter med højt THC-indhold er stor, og derfor giver et samarbejde med Udenrigsministeriets eksportrådgivning god mening.

På mødet var der naturligvis i høj grad fokus på det tjekkiske marked som afsætningsmulighed. Der blev delt information og viden omkring, hvordan markedet kan penetreres, og der blev drøftet spændende emner i forhold til samarbejdsafsnittet med lokale virksomheder og fremtiden.

Louise Conradsen udtaler:

"Vi kan drage fordel af at have rådgivning inden for eksport og investering tæt på os for at blive mere oplyste om de forskellige regulatoriske krav, der findes i Europa inden for medicinsk cannabis. At drive en startupvirksomhed kræver konstant overvågning af markedet og kapital, og jeg tror, at vi kan få stor gavn af de ressourcer, der tilbydes. Vi ser frem til et tættere samarbejde i fremtiden."

[image]

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.

The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (OTCQB: DCPXF).

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Phone: +45 2963 6920

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.